Preclinical Assessment of Efficacy and Safety Analysis of CAR-T Cells (ISIKOK-19) Targeting CD19-Expressing B-Cells for the First Turkish Academic Clinical Trial with Relapsed/Refractory ALL and NHL Patients

OBJECTIVE: Relapsed and refractory CD19-positive B-cell acute lymphoblastic leukemia (ALL) and non-Hodgkin lymphoma (NHL) are the focus of studies on hematological cancers. Treatment of these malignancies has undergone recent transformation with the development of new gene therapy and molecular biol...

Descripción completa

Detalles Bibliográficos
Autores principales: Taştan, Cihan, Kançağı, Derya Dilek, Turan, Raife Dilek, Yurtsever, Bulut, Çakırsoy, Didem, Abanuz, Selen, Yılancı, Muhammet, Seyis, Utku, Özer, Samed, Mert, Selin, Kayhan, Cavit Kerem, Tokat, Fatma, Açıkel Elmas, Merve, Birdoğan, Selçuk, Arbak, Serap, Yalçın, Koray, Sezgin, Aslıhan, Kızılkılıç, Ebru, Hemşinlioğlu, Cansu, İnce, Ümit, Ratip, Siret, Ovalı, Ercüment
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Galenos Publishing 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7702660/
https://www.ncbi.nlm.nih.gov/pubmed/32755128
http://dx.doi.org/10.4274/tjh.galenos.2020.2020.0070

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7702660/
https://www.ncbi.nlm.nih.gov/pubmed/32755128
http://dx.doi.org/10.4274/tjh.galenos.2020.2020.0070

Ejemplares similares